NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
IranIranianMilitaryIsraeliPricesStrikesCrisisRegionalOperationsMilitiasMarketsLaunchGulfConflictStatesHormuzMarchEscalationTimelineTargetsStraitDigestPowerProxy
IranIranianMilitaryIsraeliPricesStrikesCrisisRegionalOperationsMilitiasMarketsLaunchGulfConflictStatesHormuzMarchEscalationTimelineTargetsStraitDigestPowerProxy
All Articles
STAT+: Aetna’s ACA hospital prices, and a new Cigna deal
STAT News
Published about 2 hours ago

STAT+: Aetna’s ACA hospital prices, and a new Cigna deal

STAT News · Mar 2, 2026 · Collected from RSS

Summary

The health insurer paid higher prices for hospital care than some rivals in the ACA insurance market.

Full Article

You’re reading STAT’s Health Care Inc. newsletter Adobe By Bob HermanMarch 2, 2026 Business of Health Care Reporter Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09. This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here. Try this extremely fun color game. How good are you at remembering and then creating a color you see? (I got 36.73/50 — not good.) Color me impressed with all the tips and feedback you’re sending: [email protected]. Aetna paid higher prices on ACA plans Courtesy: Serif Health Aetna, the health insurance subsidiary of CVS Health, stopped selling Affordable Care Act plans this year. The company said its ACA members had too many medical claims, with CEO David Joyner noting last year, “There is not a near- or long-term pathway for Aetna to materially improve its position in this product.” STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Business of Health Care Reporter Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09.


Share this story

Read Original at STAT News

Related Articles

STAT Newsabout 5 hours ago
STAT+: A Merck cancer drug to watch

UniQure seeks approval, Novartis settles Henrietta Lacks lawsuit, and more biotech stories

STAT Newsabout 5 hours ago
A swine flu case to keep tabs on

The "godfather of vaccines," a case of swine flu, and other health news from Morning Rounds

STAT Newsabout 6 hours ago
STAT+: Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more

The most-favored nation drug pricing deals the Trump administration reached with 16 drugmakers end after three years in some cases, according to SEC filings

STAT Newsabout 7 hours ago
STAT+: UniQure plans to seek approval for Huntington’s therapy still blocked by FDA

UniQure said plans to seek approval for its Huntington’s disease treatment with the FDA remain blocked.

STAT Newsabout 10 hours ago
Opinion: I analyzed 6 months of Reddit discussion about at-home ketamine therapy. The findings alarmed me

“Telehealth ketamine has crossed the line from innovation to abdication of care,” writes Michael Alvear.

STAT Newsabout 10 hours ago
STAT+: Trump’s drive to get Europe to pay more for drugs creates uncertainty for countries, patients

President Trump's demand that wealthy countries in Europe spend more on drugs so the U.S. can pay less has introduced uncertainty across the continent.